Lilly’s New Playbook: Expanding Access to Obesity Drugs and Reshaping the Market Eli Lilly has launched “Employer Connect,” a new platform aimed at making its obesity drug, Zepbound, more accessible to employees through their health insurance. This move addresses a significant hurdle in the rapidly evolving obesity treatment landscape: cost and inconsistent employer coverage. Although … Read more
Novo Nordisk’s Setback: What the CagriSema Trial Means for the Future of Obesity Drugs Novo Nordisk’s stock experienced a significant 15% drop on Monday after announcing its next-generation weight loss drug, CagriSema, did not demonstrate superiority to Eli Lilly’s tirzepatide in a recent trial. This news arrives as Eli Lilly’s drugs, Mounjaro and Zepbound, are … Read more
Hims & Hers’ $1.15 Billion Bet on Eucalyptus: A Sign of Telehealth’s Global Expansion? Hims & Hers Health’s agreement to acquire Australian digital health company Eucalyptus for up to $1.15 billion signals a significant shift in the telehealth landscape. This move isn’t just about expanding into new markets. it’s a strategic play for a future … Read more
Hims & Hers Retreats from Wegovy Copycat: What It Means for the Future of Weight-Loss Drugs Novo Nordisk shares surged Monday after Hims & Hers announced it would discontinue sales of its cheaper, compounded version of the weight-loss pill Wegovy. The move comes after threats of legal action from Novo Nordisk and scrutiny from the … Read more
Pfizer’s Pivot: Navigating a Post-COVID World and the Future of Pharma Pfizer’s recent fourth-quarter earnings report, while exceeding Wall Street expectations, paints a clear picture: the era of blockbuster COVID-19 revenue is waning. The company is now aggressively shifting its focus, and its future hinges on strategic acquisitions, cost-cutting measures, and navigating a complex landscape … Read more
The Obesity Drug Revolution: How Medicare Coverage and Trump’s Plan Could Reshape the Market The landscape of obesity treatment is poised for a dramatic shift. Eli Lilly CEO Dave Ricks recently signaled that upcoming Medicare coverage, coupled with pricing agreements struck with the Trump administration, could be a game-changer for the rollout of their experimental … Read more
President Donald Trump announced Monday a new round of tariffs on goods imported from South Korea, increasing duties on autos, pharmaceuticals, and lumber from 15% to 25%. The action comes in response to a delay in the South Korean legislature’s approval of a trade deal initially reached with the United States last summer. Tariff Increase … Read more
The Shifting Sands of Pharma: Navigating Patent Cliffs, Deals, and a New Political Landscape The pharmaceutical industry entered 2026 with a cautious optimism, a sentiment echoing from the recent JPMorgan Healthcare Conference in San Francisco. While geopolitical uncertainties lingered in 2025, a potential turning point for the sector is on the horizon, fueled by falling … Read more
The Pill Revolution: How Oral Obesity Drugs Are Set to Reshape Weight Loss For years, the fight against obesity has largely relied on lifestyle changes and, increasingly, injectable medications like Wegovy and Mounjaro. But a significant shift is on the horizon. 2026 promises to be a pivotal year, with the anticipated arrival of convenient, daily … Read more
The Obesity Drug Race Heats Up: Beyond Wegovy and Zepbound The weight-loss drug market is no longer a two-horse race. While Novo Nordisk and Eli Lilly currently dominate headlines – and market share – a surge of smaller players and Big Pharma giants are vying for a piece of what analysts predict will be a … Read more